Patient characteristics
TNBC, tumor, mTNBC
ONCOLOGY, BRAIN METASTASES, TUMOR, CARCINOMATOUS MENINGITIS
The study recruited women with previously untreated, inoperable, locally advanced, or mTNBC who were 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, and at least one measurable lesion per RECIST v1.1. Patients agreed to provide tumor tissue for central assessment of PD-L1 and CD73 IHC status prior to randomization for stratification and a second biopsy at week 3 for translational research purposes. For patients with recurrent TNBC, a disease-free interval of at least 6 months was required. Main exclusion criteria included untreated brain metastases and/or carcinomatous meningitis, and medical contra-indications to anti-PD-L1 ICI such as ongoing steroids therapy of more than 10 mg/day of prednisone or its equivalent. A full list of inclusion and exclusion criteria is presented in the “Methods” section.